Bioinvent International AB

🇳🇴Norway

Country: 🇳🇴Norway

Ownership: Public

Established: 1983-01-01

Employees: 111

Market Cap: -

Website: http://www.bioinvent.com

Clinical Trials

BI-1910 as a Single Agent and in Combination With Pembrolizumab for the Treatment of Advanced Solid Tumors

Phase 1

Recruiting

Conditions: Solid Tumors
Non Small Cell Lung Cancer
Hepatocellular Carcinoma

Interventions: Drug: BI-1910
Drug: Pembrolizumab

First Posted Date: 2024-01-16

Last Posted Date: 2024-07-23

Lead Sponsor: BioInvent International AB

Target Recruit Count: 104

Registration Number: NCT06205706

Locations: 🇵🇱
Uniwersytecki Szpital Kliniczny, Poznań, Poland
🇵🇱
Instytut Centrum Zdrowia Matki Polki, Łódź, Poland
🇪🇸
Hospital Fundacion Jimenez Diaz, Madrid, Spain

and more 9 locations

BI-1607 in Combination with Trastuzumab in Subjects with HER2-positive Advanced Solid Tumors

Phase 1

Terminated

Conditions: HER2-positive Gastric Cancer
Metastatic Gastroesophageal Junction Adenocarcinoma
HER2-positive Metastatic Breast Cancer
HER2-positive Breast Cancer
Metastatic Gastric Adenocarcinoma

Interventions: Drug: BI-1607
Drug: Trastuzumab

First Posted Date: 2022-09-26

Last Posted Date: 2024-12-16

Lead Sponsor: BioInvent International AB

Target Recruit Count: 18

Registration Number: NCT05555251

Locations: 🇪🇸
Hospital Vall d'Hebron, Barcelona, Spain
🇪🇸
Complejo hospitalario Ruber Juan Bravo, Madrid, Spain
🇬🇧
Churchill Hospital, Oxford, United Kingdom

and more 3 locations

BI-1808 as a Single Agent and With Pembrolizumab (KEYTRUDA® ) in Treatment of Advanced Malignancies(Keynote-D20)

Phase 1

Recruiting

Conditions: Advanced Malignancies

Interventions: Drug: BI-1808
Drug: Pembrolizumab (KEYTRUDA® ) 25 Mg/mL Solution for Injection

First Posted Date: 2021-02-12

Last Posted Date: 2024-08-21

Lead Sponsor: BioInvent International AB

Target Recruit Count: 100

Registration Number: NCT04752826

Locations: 🇭🇺
PRA Health Sciences - Hungary, Budapest, Hungary
🇭🇺
Debreceni Egyetem Klinikai Központ, Debrecen, Hungary
🇭🇺
Magyar Honvédség-Egészségügyi Központ, Budapest, Hungary

and more 15 locations

A Study of BI-1206 in Combination With Pembrolizumab in Subjects With Advanced Solid Tumors (KEYNOTE-A04)

Phase 1

Recruiting

Conditions: Solid Tumor, Adult

Interventions: Drug: BI1206

First Posted Date: 2020-01-07

Last Posted Date: 2023-11-24

Lead Sponsor: BioInvent International AB

Target Recruit Count: 90

Registration Number: NCT04219254

Locations: 🇺🇸
Sarah Cannon Research Institute, Denver, Colorado, United States
🇺🇸
HealthPartners Institute - Regions Cancer Care Center,, Saint Paul, Minnesota, United States
🇸🇪
Sahlgrenska University Hospital, Göteborg, Sweden

and more 4 locations

A Study of BI-1206 in Combination With Rituximab in Subjects With Indolent B-Cell Non-Hodgkin Lymphoma

Phase 1

Recruiting

Conditions: Indolent B-Cell Non-Hodgkin Lymphoma

Interventions: Biological: BI-1206

First Posted Date: 2018-06-27

Last Posted Date: 2024-01-30

Lead Sponsor: BioInvent International AB

Target Recruit Count: 98

Registration Number: NCT03571568

Locations: 🇵🇱
Małopolskie Centrum Medyczne, Krakow, Poland
🇵🇱
Szpital Specjlistyczny, Grudziadz, Poland
🇺🇸
Emory University Hospital, Atlanta, Georgia, United States

and more 19 locations

A Phase I/II Study of BI-505 in Conjunction With Autologous Stem Cell Transplant in Multiple Myeloma

Phase 1

Terminated

Conditions: Multiple Myeloma

Interventions: Biological: BI-505
Other: High dose melphalan
Other: Autologous stem cell transplantation

First Posted Date: 2016-04-29

Last Posted Date: 2020-03-12

Lead Sponsor: BioInvent International AB

Target Recruit Count: 5

Registration Number: NCT02756728

Locations: 🇺🇸
Perelman School of Medicine/Hospital of the Univ. of Pennsylvania/Abramson Cancer Center, Philadelphia, Pennsylvania, United States

A Phase II Study of BI-505 in Smoldering Multiple Myeloma

Phase 2

Terminated

Conditions: Smoldering Multiple Myeloma

Interventions: Drug: BI-505

First Posted Date: 2013-04-24

Last Posted Date: 2023-01-11

Lead Sponsor: BioInvent International AB

Target Recruit Count: 4

Registration Number: NCT01838369

Locations: 🇸🇪
Department of Hemtaology, Skåne University Hospital, Lund, Sweden

Bioavailability Study of MLDL1278A After Subcutaneous and Intravenous Administration in Healthy Subjects

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: MLDL1278A

First Posted Date: 2011-12-07

Last Posted Date: 2012-12-11

Lead Sponsor: BioInvent International AB

Target Recruit Count: 22

Registration Number: NCT01486823

Locations: 🇬🇧
Quintiles Drug Research Unit at Guy's Hospital, London, United Kingdom

A Study of a Human Anti-Intercellular Adhesion Molecule-1 Monoclonal Antibody, in Patients With Multiple Myeloma

Phase 1

Completed

Conditions: Multiple Myeloma

Interventions: Biological: BI-505

First Posted Date: 2009-12-03

Last Posted Date: 2013-03-15

Lead Sponsor: BioInvent International AB

Target Recruit Count: 35

Registration Number: NCT01025206

Locations: 🇩🇰
Rigshospitalet, Copenhagen, Denmark
🇺🇸
University of Utah Health Sciences Center, Department of Medicine, Division of Hematology, Utah Blood and Marrow Transplant and Myeloma Program, Salt Lake City, Utah, United States
🇺🇸
University of Maryland, Greenebaum Cancer Center, Baltimore, Maryland, United States

and more 4 locations

Phase I Study on Monoclonal Antibody TB-403 Directed Against PlGF in Patients With Solid Tumours

Phase 1

Completed

Conditions: Solid Tumors

Interventions: Biological: TB-403

First Posted Date: 2008-06-20

Last Posted Date: 2022-03-16

Lead Sponsor: BioInvent International AB

Target Recruit Count: 21

Registration Number: NCT00702494

Locations: 🇩🇰
Onkologisk Klinik 5072 Finsencentret Rigshospitalet, Copenhagen, Denmark
🇩🇰
Onkologisk Afdeling 54B1 Herlev Hospital, Herlev, Denmark

Prev
1
Next

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy